Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease

Research output: Contribution to journalArticlepeer-review

46 Downloads (Pure)

Abstract

Unfractionated heparin has multiple pharmacological activities beyond anticoagulation. These anti-inflammatory, anti-microbial, and mucoactive activities are shared in part by low molecular weight and non-anticoagulant heparin derivatives. Anti-inflammatory activities include inhibition of chemokine activity and cytokine synthesis, inhibitory effects on the mechanisms of adhesion and diapedesis involved in neutrophil recruitment, inhibition of heparanase activity, inhibition of the proteases of the coagulation and complement cascades, inhibition of neutrophil elastase activity, neutralisation of toxic basic histones, and inhibition of HMGB1 activity. This review considers the potential for heparin and its derivatives to treat inflammatory lung disease, including COVID-19, ALI, ARDS, cystic fibrosis, asthma, and COPD via the inhaled route.
Original languageEnglish
Article number584
Number of pages26
JournalPharmaceuticals
Volume16
Issue number4
DOIs
Publication statusPublished - 13 Apr 2023

Keywords

  • heparin
  • inflammation
  • coagulation
  • COVID-19
  • ALI
  • ARDS
  • cystic fibrosis
  • asthma
  • COPD

Cite this